DUSP4 upregulation was observed when comparing HCC cells and HCC cells treated with 2 μM Selumetinib, indicating that MEK inhibition could upregulate DUSP4 expression in HCC cells (Figure 6B). The gene discussed is MAP2K7; the disease is hepatocellular carcinoma.